Common use of INCORPORATION OF INFORMATION BY REFERENCE Clause in Contracts

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024; • our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the SEC on May 9, 2024; • our Current Report on Form 8-K filed with the SEC on February 29, 2024 and June 6, 2024 (excluding any information furnished in such report under Item 2.02 or Item 7.01); • the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on September 27, 1995 (paper filing) under Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.12 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness of the registration statement. We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). You may request a copy of these filings (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost by writing, telephoning or e-mailing us at the following address, telephone number or e-mail address: Copies of these filings are also available through the “Investors” section of our website at xxx.xxxxxxxxxxxxxxxxxxx.xxx. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with the SECit, which means that we can disclose important information to you by referring you to those other documents. The information incorporated which we incorporate by reference is an important part of this prospectus supplement and the accompanying prospectus, and certain information that we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the following documents listed below (File No. 001-31938): • our Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 28, 2020; • our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and any future filings September 30, 2020, filed on May 8, 2020, August 7, 2020 and November 6, 2020; respectively; and • our Current Reports on Form 8-K, filed on January 15, 2020, June 16, 2020, June 26, 2020, July 14, 2020, July 24, 2020, July 31, 2020, August 28, 2020, August 31, 2020, October 5, 2020, October 19, 2020, December 1, 2020, December 21, 2020, December 31, 2020 and January 13, 2021. In addition, all reports and other documents that we make with the SEC under subsequently file pursuant to Section 13(a), 13(c), 14, 14 or 15(d) of the Exchange Act prior to the termination of this offering, but excluding any offering information furnished to, rather than filed with, the SEC, will be deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to be part of securities made by this prospectus: • prospectus supplement and the accompanying prospectus from the time of the filing of such reports and documents. You may access our Annual Report on Form 10-K for the fiscal year ended December 31K, 2023, filed with the SEC on March 28, 2024; • our Quarterly Report Reports on Form 10-Q for the fiscal quarter ended March 31Q, 2024, filed with the SEC on May 9, 2024; • our Current Report Reports on Form 8-K filed with and amendments to any of these reports, free of charge on the SEC on February 29SEC’s website. Information contained on, 2024 and June 6or that can be accessed through, 2024 (excluding any information furnished in such report under Item 2.02 or Item 7.01); • the description our website is not part of our common stock contained in our registration statement on Form 8-A filed with the SEC on September 27, 1995 (paper filing) under Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.12 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a partsupplement and the accompanying prospectus. In addition, and prior to the effectiveness of the registration statement. We we will furnish without charge to you, on written or oral request, a copy of any or all of such the documents that has been incorporated herein by reference (reference, other than exhibits to such those documents. You should direct any requests for documents unless such exhibits to Corporate Secretary, Acorda Therapeutics, Inc., 000 Xxx Xxxx Xxxxx Xxxx, Xxxxxxx, Xxx Xxxx 00000, or call (000) 000-0000. We are specifically responsible for the information contained or incorporated by reference into the documents that in this prospectus incorporates)supplement, the accompanying prospectus and in any related free-writing prospectus we prepare or authorize. We have not authorized anyone to give you any other information, and we take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are not making offers to sell or seeking offers to buy these securities in any jurisdiction where the offer or sale is not permitted. You may request a copy of these filings (other than an exhibit to a filing unless should assume that exhibit is specifically the information contained in or incorporated by reference into that filing) at no cost by writing, telephoning or e-mailing us at in this prospectus supplement and the following address, telephone number or e-mail address: Copies accompanying prospectus is accurate as of these filings are also available through the “Investors” section of our website at xxx.xxxxxxxxxxxxxxxxxxx.xxx. See date on the section front of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies supplement, the accompanying prospectus or incorporated document only, as the case may be. Our business, financial condition, results of materials operations and prospects may have changed since that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectusdate.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” the information that we file with the SECit, which means that we can disclose important information to you by referring you to those other documents. The information incorporated we incorporate by reference is an important part of this prospectus, and certain information that we will later file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and below, as well as any future filings we make made with the SEC under Section Sections 13(a), 13(c), 14, 14 or 15(d) of the Exchange Act from the date of the initial registration statement and prior to the termination effectiveness of this registration statement, and any offering filings made after the date of this prospectus until we sell all of the securities made by under this prospectus, except that we do not incorporate any document or portion of a document that was furnished and deemed by the rules of the SEC not to have been filed: • our ● Our Annual Report on Form 10-K for the fiscal year ended December 31June 30, 20232020, filed with the SEC on March September 28, 20242020; • our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, filed with the SEC on May 9, 2024; • our and ● Our Current Report on Form 8-K filed with the SEC on February 29October 1, 2024 2020; and June 6, 2024 (excluding any information furnished in such report under Item 2.02 or Item 7.01); • the ● The description of our common stock contained set forth in Item 1 of our registration statement Registration Statement on Form 8-A filed with the SEC on September 27August 6, 1995 (paper filing2020, pursuant to Section 12(b) under Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description. Additionally, including Exhibit 4.12 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019; all reports and • filings we make with the SEC other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the effective date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness termination or completion of this offering, shall be deemed to be incorporated by reference in this prospectus and to be part hereof from the registration statementdate of filing of such reports and other documents. Any information that we subsequently file with the SEC that is incorporated by reference as described above will automatically update and supersede any previous information that is part of this prospectus. We will furnish hereby undertake to provide without charge to youeach person, on including any beneficial owner, to whom a copy of this prospectus is delivered, upon written or oral requestrequest of any such person, a copy of any or and all of such documents the information that has been or may be incorporated herein by reference (in this prospectus, other than exhibits to such documents unless documents. Requests for such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). You may request a copy of these filings copies should be directed to our Secretary at 0000 X. Xxxxxxx Xxxxx, Xxxxx XX, 00000; Telephone (other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing000) at no cost by writing, telephoning or e000-mailing us at the following address, telephone number or e-mail address: Copies of these filings are also available through the “Investors” section of our website at xxx.xxxxxxxxxxxxxxxxxxx.xxx. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus0000.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede supercede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: • our Annual Report on Form 10-K (File No. 033-80623) for the fiscal year ended December 31, 2023, 2017 filed with the SEC on March 281, 20242018, including certain information incorporated by reference therein from our Definitive Proxy Statement on Schedule 14A for our 2018 annual meeting of stockholders filed with the SEC on April 19, 2018; • our Quarterly Report Reports on Form 10-Q (File Nos. 033-80623) for the fiscal quarter ended March 31, 20242018, filed with the SEC on May 9, 20242018 and amended on May 23, 2018, and for the quarters endedJune 30, 2018 and September 30, 2018, filed with the SEC on August 8, 2018 and November 7, 2018, respectively; • our Current Report current reports on Form 8-K (File Nos. 033-80623) filed with the SEC on February 29January 24, 2024 2018, May 23, 2018, June 20, 2018, September 21, 2018, September 28, 2018, and June 6October 1, 2024 (excluding any information furnished in such report under Item 2.02 or Item 7.01)2018; • the description of our common stock contained in our registration statement on Form 8Form8-A (File No. 000-21243) filed with the SEC Commission on September 27, 1995 (paper filing) under Section 12 of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.12 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness of the registration statement. We will furnish without charge to you, on Upon written or oral request, we will provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of any or all of such documents that has been are incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). You may request a copy of these filings (other than an exhibit Written or oral requests for copies should be directed to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost by writingAchieve Life Sciences, telephoning or e-mailing us at the following addressInc., 0000 X. Xxxxxxxx, Xxxxx 000, Xxxxxxxxx, XX X0X 0X0, Attn: Xxxxxx Xxxxxxx, telephone number or e(000) 000-mail address: Copies of these filings are also available through the “Investors” section of our website at xxx.xxxxxxxxxxxxxxxxxxx.xxx. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC0000. Any statement contained in this prospectus, or in a document, document all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.

INCORPORATION OF INFORMATION BY REFERENCE. The SEC allows us to “incorporate by reference” information that we file with the SEC, which means that we can disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information we file later with the SEC will automatically update and supersede this information. A Current Report (or portion thereof) furnished, but not filed, on Form 8-K shall not be incorporated by reference into this prospectus. We incorporate by reference the documents listed below and any future filings we make with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the termination of any offering of securities made by this prospectus: • our Annual Report on Form 10-K for the fiscal year ended December 31, 20232019, filed with the SEC on March 283, 20242020; • our Quarterly Report Reports on Form 10-Q for the fiscal quarter quarters ended March 31, 20242020 and June 30, 2020, filed with the SEC on May 97, 20242020 and August 6, 2020, respectively; • our Current Report Reports on Form 8-K filed with the SEC on January 21, 2020, January 22, 2020, February 296, 2024 2020, April 16, 2020, May 26, 2020, June 3, 2020, and June 611, 2024 2020; • our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 24, 2020 (excluding any but only with respect to information furnished in such report under Item 2.02 or Item 7.01required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2019); • the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on September 27July 8, 1995 (paper filing) 2015 under Section 12 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description, including Exhibit 4.12 4.5 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 3, 2020; and • filings we make with the SEC pursuant to the Exchange Act after the date of the initial registration statement, of which this prospectus is a part, and prior to the effectiveness of the registration statement. We will furnish without charge to you, on written or oral request, a copy of any or all of such documents that has been incorporated herein by reference (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into the documents that this prospectus incorporates). You may request a copy of these filings (other than an exhibit Written or oral requests for copies should be directed to a filing unless that exhibit is specifically incorporated by reference into that filing) at no cost by writingSierra Oncology, telephoning or e-mailing us at the following addressInc., 0000 – 000 Xxxx Xxxxxxx Xxxxxx, Xxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxx X0X 0X0, and our telephone number or eis (000) 000-mail address: Copies of these filings are also available through the “Investors” section of our website at xxx.xxxxxxxxxxxxxxxxxxx.xxx0000. See the section of this prospectus entitled “Where You Can Find More Information” for information concerning how to obtain copies of materials that we file with the SEC. Any statement contained in this prospectus, or in a document, all or a portion of which is incorporated by reference, shall be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or any document incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not, except as so modified or superseded, constitute a part of this prospectus.